Rosiglitazone Effect on Mitochondria and Lipoatrophy

Completed · Phase 2 · Has a placebo group

Conditions studied: HIV Infections

In brief

The purpose of this study is to examine the effect of rosiglitazone on limb fat and mitochondrial indices in HIV-1-infected subjects receiving stable antiretroviral therapy that does not contain stavudine (d4T) or zidovudine (AZT).

Key facts

Study ID

NCT00367744

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

71

Starts

2006-07-01

Expected to finish

2008-12-01

Last updated by the study team

2017-02-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Lipoatrophy
• Thymidine sparing ARV for at least 24 weeks
• Prior thymidine NRTIs for at least 12 months

You may not qualify if…

• Diabetes
• Heart failure
• Liver disease
• Hormonal therapies

Where it is running

• Cleveland Clinc Foundation — Cleveland, Ohio, United States
• University Hospitals of Cleveland/Case Western Reserve University — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.